Eric Coldwell: And then on margin in Drug Development. I thought I heard you say you expected flat margin here in Q1. Can you confirm that, so something around 11.5%? Is that reasonable?
Adam Schechter: Yes. So we’re assuming that the margin will be flat versus this margin last year. So I think that’s about right. The big issue there is the fact that we are not going to have the supply of the NHPs in the first quarter. And therefore, we won’t be able to — we’ll have most of that $80 million to $100 million impact because a lot of it flows through because we still have all of the people and hiring net for that group. We have the facilities and so forth. So we’re not making any changes to try to manage that margin because we know the supply is coming in. So that will be the toughest quarter. There might be a little bit slow over the second quarter. But overall, we expect that we’ll have some margin appreciation for the Drug Development business for the full year with the second half certainly being better than the first half.
Eric Coldwell: Great. And then last one for me, if I can. Central lab has apparently one more tough quarter on last year’s activity. Q1 ’22 was pretty solid. Are you expecting central lab to be back to growth by the second quarter? And can you give any updates on how those past kits that were sent didn’t come back? Are you seeing any changes in dynamics in terms of order flow on kits or returns on kits? Just trying to get a better sense on when we can expect the central lab business to resume year-over-year growth?
Adam Schechter: Yes. So the first quarter of 2019, we were still doing a lot of COVID-related work, particularly for the booster shots for Omicron. So that will be the toughest quarter of next year will be the first quarter. As I look at quarters in that business, they look great. And I’m actually very optimistic about our central laboratory business moving forward. I think we’re just overlapping tough comparisons. But book-to-bill orders I mean everything I look at for the business is good. We are not yet at the kit return level that we were at in 2019. I still think that some sites are struggling to enroll as many patients that they have in the past. But we are seeing the kit returns increase month-over-month. And I feel confident that we’ll continue to see that as we go through this year.
Glenn Eisenberg: Eric, the only thing I’d add to that is, to your point, the first quarter will be the one that would be down year-on-year before things annualize and then we’ll look at good growth throughout the remainder of the year but we’ll still have that constraint. We’ve talked about that we’re still going to see — while the supply chain issues which was really more of a ’21 issue. So we were down in ’22 from the supply, ’22 supply levels were more normalized. So the year-on-year COVID-related impact will still be with us doing less vaccine and therapeutic work in ’23 than we did in ’22. Even with that headwind, that again, we sized up at around $90 million, so call it 0.5 points for the overall segment. Obviously, it’s a bigger constraint when you just look at it because it’s mostly within our central lab business. But even with that headwind, we still expect to see very good top line growth throughout the 3 quarters, second, third and fourth quarter of ’23.
Operator: Our next question comes from Derek DeBruin of Bank of America.
